Disclosures The authors stated that they have no interests which might be perceived as posing a conflict or bias.
Efficacy and long-term immunogenicity of hepatitis B vaccine in haemodialysis patients
Article first published online: 14 NOV 2007
© 2007 The Authors. Journal compilation © 2007 Blackwell Publishing Ltd
International Journal of Clinical Practice
Volume 63, Issue 3, pages 394–397, March 2009
How to Cite
Ramezani, A., Eslamifar, A., Banifazl, M., Ahmadi, F., Maziar, S., Razeghi, E., Kalantar, E., Amirkhani, A. and Aghakhani, A. (2009), Efficacy and long-term immunogenicity of hepatitis B vaccine in haemodialysis patients. International Journal of Clinical Practice, 63: 394–397. doi: 10.1111/j.1742-1241.2007.01470.x
- Issue published online: 2 FEB 2009
- Article first published online: 14 NOV 2007
- Paper received March 2007, accepted May 2007
Background: Hepatitis B vaccine is effective in protection against hepatitis B virus (HBV) infection in haemodialysis (HD) patients, but the antibody response is variable in this population and the persistence of immunity in them remains largely unknown. In this study we aimed to evaluate the efficacy and long-term immunogenicity of hepatitis B vaccine in HD patients.
Methods: In this study, we initially offered HBV vaccination as double dose, four vaccine series schedule (40 μg injections intramuscularly in the deltoid muscle at 0, 1, 2 and 6 months) to 54 HD patients who were negative for hepatitis B core antibody and did not receive any dose of HBV vaccine previously. Serum levels of hepatitis B surface antibody (anti-HBs) tested 1–2 months after completion of vaccination. Then we follow the patients up to 1 year after primary vaccination to evaluate the persistence of immunity (as indicated by serum levels of anti-HBs higher than or equal to 10 IU/l).
Results: After primary vaccination, 87% of patients developed anti-HBs levels above 10 IU/l. 27.8% and 59.2% of them were weak responders and high responders respectively. 13% of patients were non-responders. After 1-year follow-up, 18.18% of responders had lost their anti-HBs (transient responders). All of them were initially in weak responders group and had lower anti-HBs levels.
Conclusion: We found an average percentage of seroconversion after primary HBV vaccination in HD patients. Our study also supported this fact that an antibody titre above 100 IU/l following primary vaccination is necessary to maintain that level of antibody 1 year later.